Sienna Biopharmaceuticals, Inc. – With No Revenue and Unsustainable Cash Burn, Biopharmaceutical Start-Up Seeks Refuge in Chapter 11

September 16, 2019− Sienna Biopharmaceuticals, Inc. (NASDAQ Global Select Market: “SNNA," “Sienna” or the “Debtor”) filed for Chapter 11 protection with the U.S. Bankruptcy Court in the District of Delaware, lead case number 19-12051. The Debtor, a clinical-stage biopharmaceutical and medical device company focused on skin therapies, is represented by Michael R Nestor of Young…